BURGER DENIS R 4
4 · Aptose Biosciences Inc. · Filed Jul 1, 2026
Research Summary
AI-generated summary of this filing
Aptose (APTO) Former Director Denis Burger Sells 528,737 Shares
What Happened
Denis R. Burger, a former director of Aptose Biosciences (APTO), disposed of a total of 528,737 securities on June 30, 2026. The transactions were dispositions to the issuer pursuant to a board-, shareholder- and court‑approved business arrangement under which Hammi Pharmaceuticals acquired all outstanding shares at C$2.41 per share. Using the filing’s conversion (C$1.40 = US$1.00), the aggregate consideration is approximately US$909,428. The Form 4 shows one cash amount (70 shares at US$1.72, $120) and multiple $0 entries because many items were derivative instruments (options/awards) being surrendered/converted in the deal.
Key Details
- Transaction date: 2026-06-30; Form 4 filed 2026-07-01.
- Disposed: 528,737 total securities (includes stock and multiple derivative/option line items).
- Reported price: C$2.41 per share (converted in filing to US$1.72 per share); total ≈ US$909,428.
- Shares owned after transaction: Not specified in the filing.
- Footnotes: F1 = dispositions were pursuant to the business arrangement with Hammi Pharmaceuticals; F2 = currency conversion C$1.40 = US$1.00; F3 = option vesting schedule noted.
- Filing timeliness: No late-filing indication in the document.
Context
Most of the reported line items are derivative dispositions (options or option-like awards) recorded at $0 in the Form 4 because they were surrendered, converted, or cancelled as part of the acquisition transaction. Dispositions tied to an M&A closing are routine outcomes of deal consideration and corporate reorganization; they reflect the transaction, not necessarily the insider’s ongoing market view.
Insider Transaction Report
- Disposition to Issuer
Common Shares
[F1][F2]2026-06-30$1.72/sh−70$120→ 0 total - Disposition to Issuer
Director Stock Option (Right to Buy)
[F1][F3]2026-06-30−3,333→ 0 totalExercise: $2.00Exp: 2034-02-05→ Common Shares (3,333 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
[F1][F3]2026-06-30−100,000→ 0 totalExercise: $0.66Exp: 2033-01-19→ Common Shares (100,000 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
[F1][F3]2026-06-30−50,000→ 0 totalExercise: $1.34Exp: 2032-01-17→ Common Shares (50,000 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
[F1][F3]2026-06-30−50,000→ 0 totalExercise: $4.37Exp: 2031-01-04→ Common Shares (50,000 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
[F1][F3]2026-06-30−50,000→ 0 totalExercise: $5.15Exp: 2030-03-10→ Common Shares (50,000 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
[F1][F3]2026-06-30−160,334→ 0 totalExercise: $6.91Exp: 2030-01-30→ Common Shares (160,334 underlying) - Disposition to Issuer
Stock Options (Right to Buy)
[F1][F3]2026-06-30−40,000→ 0 totalExercise: $1.91Exp: 2029-01-02→ Common Shares (40,000 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
[F1][F3]2026-06-30−5,000→ 0 totalExercise: $1.03Exp: 2027-06-06→ Common Shares (5,000 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
[F1][F3]2026-06-30−60,000→ 0 totalExercise: $2.80Exp: 2028-01-19→ Common Shares (60,000 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
[F1][F3]2026-06-30−10,000→ 0 totalExercise: $1.14Exp: 2027-03-28→ Common Shares (10,000 underlying)
Footnotes (3)
- [F1]Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a purchase price of C$2.41 per share.
- [F2]Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00.
- [F3]Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date.